Observational studyAdvances in rheumatology (London, England)2025

Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with rheumatoid arthritis: a 12-month observational study.

Fanny Reyes-Neira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.